| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TMOD1 |
| Uniprot No | P28289 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MSYRRELEKYRDLDEDEILGALTEEELRTLENELDELDPDNALLPAGLRQKDQTTKAPTGPFKREELLDHLEKQAKEFKDREDLVPYTGEKRGKVWVPKQKPLDPVLESVTLEPELEEALANASDAELCDIAAILGMHTLMSNQQYYQALSSSSIMNKEGLNSVIKPTQYKPVPDEEPNSTDVEETLERIKNNDPKLEEVNLNNIRNIPIPTLKAYAEALKENSYVKKFSIVGTRSNDPVAYALAEMLKENKVLKTLNVESNFISGAGILRLVEALPYNTSLVEMKIDNQSQPLGNKVEMEIVSMLEKNATLLKFGYHFTQQGPRLRASNAMMNNNDLVRKRRLADLTGPIIPKCRSGV |
| 预测分子量 | 67.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TMOD1重组蛋白的3篇文献概览(文献信息为模拟示例，仅供参考)：
1. **文献名称**：*Recombinant Tropomodulin 1 (TMOD1) regulates actin filament dynamics in vitro*
**作者**：Smith A, et al.
**摘要**：研究利用重组TMOD1蛋白，通过体外实验验证其对肌动蛋白丝末端封端的作用，发现TMOD1通过结合肌动蛋白和原肌球蛋白抑制微丝伸长，揭示了其在细胞骨架稳定性中的关键机制。
2. **文献名称**：*Structural insights into TMOD1’s role in erythrocyte membrane stability*
**作者**：Lee B, et al.
**摘要**：通过重组表达人源TMOD1蛋白并结合X射线晶体学分析，解析了其与F-肌动蛋白结合的分子结构，阐明了TMOD1缺陷导致红细胞形态异常的分子基础。
3. **文献名称**：*TMOD1 overexpression in cardiomyocytes disrupts sarcomere organization via recombinant protein delivery*
**作者**：Chen X, et al.
**摘要**：利用重组TMOD1蛋白转导技术，证明其在心肌细胞中异常表达会干扰肌节组装，提示TMOD1平衡对维持心脏收缩功能至关重要。
(注：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar等平台检索确认。)
**Background of TMOD1 Recombinant Protein**
Tropomodulin 1 (TMOD1) is a critical regulatory protein involved in stabilizing actin filaments, the primary structural components of the cytoskeleton. It belongs to the tropomodulin family, known for its ability to cap the pointed ends of actin filaments, preventing their depolymerization or uncontrolled elongation. TMOD1 specifically interacts with tropomyosin and actin, forming a ternary complex that ensures the stability and organization of actin networks. This function is vital in cells requiring precise cytoskeletal architecture, such as erythrocytes (red blood cells) and muscle cells. In erythrocytes, TMOD1 maintains membrane integrity by stabilizing the spectrin-actin lattice, while in striated muscle, it regulates thin filament length, impacting sarcomere structure and contractility.
The recombinant form of TMOD1 is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to generate high-purity protein for research and therapeutic applications. Recombinant TMOD1 retains its native binding properties, enabling studies on its structural interactions, kinetic behavior, and regulatory roles in cellular processes. It has been instrumental in elucidating mechanisms underlying diseases linked to cytoskeletal dysfunction, including cardiomyopathies, hemolytic anemias, and neuromuscular disorders. Additionally, TMOD1 recombinant protein serves as a tool for drug discovery, particularly in targeting cytoskeletal abnormalities.
Recent studies also explore TMOD1's involvement in non-muscle cells, such as neurons and epithelial cells, highlighting its broader role in cell motility, differentiation, and mechanotransduction. Its dual role as a stabilizer and dynamic modulator of actin underscores its biological versatility, making TMOD1 a focal point in cell biology and pathophysiology research.
×
